Biosimilars remain a hot topic with news yesterday that Indian generic drug giant Cipla, who only last week was praised by former president Bill Clinton, has launched the first Rheumatoid Arthritis biosimilar of Pfizer and Amgen?s blockbuster Enbrel. With its successes in producing generic chemical…
Biosimilars is the topic of the day as news broke of Indian Agila Biotech?s joint venture with US Pfenex Inc to produce Biosimilar products. Under the agreement Agila Biotech will hold 51% equity of the joint venture that will take advantage of…
There has been considerable amount of debate on what discount rates should be used in each and every phases of a biotech project. Should you use the cost of capital of the company while evaluating projects? The answer is clearly…
India?s generic drug manufacturers have received a large amount of negative press in the last few weeks and it is at times like this that it is important to remind ourselves of the key role these companies play in combating…
Shasun Pharmaceuticals and Debiopharm Group have entered into a licensing agreement to manufacture and commercialise the acetylcholinesterase inhibitor “Huperzine-A” (HupA) that has been shown to improve cognitive performance in patients that suffer from Alzheimer?s Disease (AD). According to the deal, Shasun Pharmaceuticals…
It is true that accounting is inconsistent in dealing with capital expenditures and operating expenditures of manufacturing firms vs technology or R&D based firms. The operating expenditures are designed to generate benefits in the current year whereas capital expenditures are…
How many times have we seen this designation in the corporate world? Does it ring any bell to you? Before we delve into this discussion, let us understand the background of why we need Board of Directors. We, as a…
Every company has two types of assets that creates value –1. Existing assets 2. Growth assets. For many matured companies such as Merck (NYSE: MRK),most of the value comes from the existing assets i.e. existing products, brands etc. For many…
Blame it on the bias during the valuation process, one tends to favor its value depending on which side of the negotiation table he or she is. One of the tools used to push the value up or down is…
The assumptions for valuations are so subjective that you would find myriad views on that. However, it is also true that those assumptions should be well backed with good evidence or rationale. Recently, I had a discussion on real options…